Drug Regulation

FDA Quality Control FDA Approval Controlled Substances DEA FDA Operations Synthetic Opioids FDA Approval Process Clinical Trials Prescription Painkillers Pharmaceutical Oversight FDA Oversight

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

The company is targeting an FDA IND in 2027 contingent on supportive preclinical data.